medigraphic.com
ISSN 2683-1678 (Print)
Órgano Oficial de la Sociedad
Latinoamericana de lnfectología Pediátrica.
Órgano de la Asociación Mexicana de
Infectología Pediátrica, A.C.
Órgano difusor de la Sociedad Española
de lnfectología

2025, Number S1

<< Back

Rev Latin Infect Pediatr 2025; 38 (S1)

Consensus of the Mexican Association of Pediatric Infectious Diseases for the diagnosis, treatment, and prevention of dengue fever in children in Mexico

Otero MFJ, Ortiz IFJ, Betancourt CM, Arias GE, Carmona VAJ, Chacón SJC, Castellanos JM, López HA, Martínez APA, Martínez LCA, Martínez NJG, Mercado DCU, Moreno ES, Neme DGA, Ortiz CB, Pérez RVM, Rivera MER, Sánchez CYH, Ulin OF, González SN

Language: Spanish
References: 65
Page: s29-51
PDF size: 835.34 Kb.


ABSTRACT

Introduction: dengue represents a severe global public health challenge and a rising burden in Mexico, showing a historical increase in cases. Children and adolescents (0-19 years) account for between 30 and 40% of cases during epidemic years in the country, underscoring the underestimation of the disease's true impact in this age group. Objective: the purpose of the Mexican Association of Pediatric Infectious Diseases (AMIP) is to generate and disseminate an updated academic consensus based on the best scientific evidence. This document aims to review the epidemiological status of dengue in Mexico, detail advances in diagnosis and treatment, and analyze immunoprevention alternatives to facilitate clinical decision-making in the pediatric population. Material and methods: an academic consensus model was employed, based on a selective literature search in databases such as PubMed, Google Scholar, and Cochrane (prioritizing articles from 2020-2025), complemented by expert opinion. Recommendations were validated using the modified GRADE synthesis table, and were integrated by a multidisciplinary team of specialists in pediatrics, infectology, and vaccinology. Results: dengue in Mexico is hyperendemic, showing shifts in circulating serotypes, with DENV-3 and DENV-4 predominating in recent years. The pediatric clinical presentation is often non-specific, with a high prevalence of vomiting and skin rash. Diagnostic tests are phase-guided (NS1/PCR in the febrile phase and IgM later). Adequate fluid management is vital; blood product transfusion is restricted to active bleeding or severe thrombocytopenia (< 10,000/µL) with invasive risk. Currently, the TAK-003 vaccine (Qdenga ®) is a promising tool, showing an overall efficacy of 61.2% against virologically confirmed dengue and 84.1% against hospitalization, with a favorable risk profile compared to CYD-TDV. Conclusion: the burden of dengue in the Mexican child population requires an evidence-based diagnostic and therapeutic approach. Vector control through integrated vector management (IVM) and the strategic incorporation of vaccines like Qdenga ® are key tools for reducing morbidity and mortality, particularly the progression to severe dengue, with no evidence supporting the use of corticosteroids or conventional antiviral therapies.


REFERENCES

  1. Centers for Disease Control and Prevention (CDC). Current Dengue Outbreak [Internet]. 2025 [Cited 2025 Aug 7]. Available in https://www.cdc.gov/dengue/outbreaks/2024/index.html

  2. World Health Organization (WHO). Dengue - Global situation [Internet]. 2024 [Cited 2025 Aug 7]. Available in: https://www.who.int/emergencies/disease-outbreak-news/item/2024-DON518

  3. Pan American Health Organization (PAHO/WHO). Dengue: data and analysis. [Internet]. [Cited 2025 Aug 7]. Available in: https://www.paho.org/en/arbo-portal/dengue-data-and-analysis

  4. Ferrario DC, Califano DG, Durán P, Maccarone DM, Miceli DI, Manterola A et al. Lineamientos para la elaboración de Consensos Guidelines for planning consensus Sociedad Argentina de Pediatría Subcomisiones, Comités y Grupos de Trabajo. Arch Argent Pediatr. 2012; 110 (2): 163-167. Disponible en: http://dx.doi.org/10.5546/aap.2012.163

  5. AGREE Trust. The AGREE Collaboration. Appraisal of Guidelines for Research & Evaluation (AGREE) Instrument. Available in: https://www.agreetrust.org/resource-centre/the-originalagree-instrument/

  6. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64 (4): 383-394. Available in: https://pubmed.ncbi.nlm.nih.gov/21195583/

  7. Servín MMF, Flores GJA, Partiño LMI, Pierdant PM. Lectura y elaboración de revisiones sistemáticas y metaanálisis en el área de la salud. 2023.

  8. WHO. Dengue [Internet]. 2025 [Cited 2025 Aug 31]. Available in: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

  9. WHO/PAHO. ARBO Portal [Internet]. 2025 [Cited 2025 Aug 31]. Available in: https://www.paho.org/es/arbo-portal

  10. PAHO/WHO. 2025. 9AD. Dengue epidemiological situation in the region of the americas - epidemiological week 32, 2025. [Cited 2025 Aug 31] Available in: https://www.paho.org/en/documents/dengue-epidemiological-situation-region-americas-epidemiological-week-32-2025

  11. Sistema Nacional para la Vigilancia Epidemiológica (SINAVE). Boletín Epidemiológico Sistema Nacional de Vigilancia Epidemiológica Sistema Único de Información 2024 [Internet]. 2025 [Citado 2025 Agosto 31]. Disponible en: https://www.gob.mx/salud/documentos/boletinepidemiologico-sistema-nacional-de-vigilancia-epidemiologica-sistema-unico-de-informacion-355523

  12. IHME. VizHub-GBD Compare [Internet]. [Cited 2025 Aug 31]. Available in: https://vizhub.healthdata.org/gbd-compare/

  13. Paz-Bailey G, Adams LE, Deen J, Anderson KB, Katzelnick LC. Dengue. Lancet. 2024; 403 (10427): 667-682. Available in: https://www.thelancet.com/action/showFullText?pii=S014067362302576X

  14. Pan American Health Organization (PAHO). Dengue: guidelines for patient care in the Region of the Americas. 2nd edition. 2016. Available in: https://iris.paho.org/handle/10665.2/31207

  15. Akram A, Akram L, Ghosh UK, Abiduzzaman MF, Rahman S. Gastrointestinal manifestations of dengue fever among children: a multicenter cross-sectional study in Bangladesh. Bangladesh Journal of Medical Microbiology. 2023; 17 (2): 66-70. Available in: https://www.banglajol.info/index.php/BJMM/article/view/69294

  16. Reyes BML, Contreras VLM, Rojas SMB, Aguilera SM, Olmos PMLE. Manifestaciones clínicas y hallazgos de laboratorio en pacientes pediátricos con diagnóstico presuntivo de infección por el virus dengue en un hospital de segundo nivel en Irapuato: serie de casos. Rev Latin Infect Pediatr. 2024; 37 (4): 156-162.

  17. Pan American Health Organization (PAHO/WHO). Algoritmos para el manejo clínico de los casos de dengue programa regional de enfermedades arbovirales algoritmos para el manejo clínico de casos de dengue contenido. 2020.

  18. Rodrigo C, Sigera C, Fernando D, Rajapakse S. Plasma leakage in dengue: a systematic review of prospective observational studies. BMC Infect Dis. 2021; 21 (1): 1-11. Available in: https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-021-06793-2

  19. Abhinayaa J, James S, Jebaraj R, Vinoth PN. Incidence of cardiac manifestations in children with dengue fever: a cross-sectional study. Rambam Maimonides Med J. 2021; 12 (2): e0014. Available in: https://pubmed.ncbi.nlm.nih.gov/33938801/

  20. Yung CF, Lee KS, Thein TL, Tan LK, Gan VC, Wong JGX, et al. Dengue serotype-specific differences in clinical manifestation, laboratory parameters and risk of severe disease in adults, Singapore. Am J Trop Med Hyg. 2015; 92 (5): 999-1005. Available in: https://pubmed.ncbi.nlm.nih.gov/25825386/

  21. De Souza LJ, Bastos PL, Carvalho ML, Assed de SL, Barbosa TRM, do Vale da Silveira M et al. Comparison of clinical and laboratory characteristics between children and adults with dengue. The Brazilian Journal of Infectious Diseases. 2013; 17 (1): 27-31. Available in: https://www.sciencedirect.com/science/article/pii/S1413867012002619?via%3Dihub

  22. Setrkraising K, Kittitrakul C. Gastrointestinal manifestations and prognostic factors for severe dengue in thai children. Am J Trop Med Hyg. 2025; 112 (3): 642-647. Available in: https://www.ajtmh.org/view/journals/tpmd/112/3/article-p642.xml

  23. Silva ÁSAD, Carvalho FL, Pinto GA, Saad LSR, Curado MO, Dombroski TCD et al. Analysis of signs and symptoms in confirmed cases of severe dengue among children aged 0 to 10 years old. Einstein (Sao Paulo). 2024; 22: eAO0546. Available in: https://pubmed.ncbi.nlm.nih.gov/38695477/

  24. Huy BV, Toan NV. Prognostic indicators associated with progresses of severe dengue. PLoS One. 2022; 17 (1): e0262096. Available in: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0262096

  25. Sangkaew S, Ming D, Boonyasiri A, Honeyford K, Kalayanarooj S, Yacoub S et al. Risk predictors of progression to severe disease during the febrile phase of dengue: a systematic review and meta-analysis. Lancet Infect Dis. 2021; 21 (7): 1014-1026. Available in: https://pubmed.ncbi.nlm.nih.gov/33640077/

  26. Salazar FJE, Marín VK, Segura CAM, Restrepo JBN, Ortega DYE, Giraldo CLS et al. Clinical manifestations of dengue in children and adults in a hyperendemic region of Colombia. Am J Trop Med Hyg. 2024; 110 (5): 971-978. Available in: https://pubmed.ncbi.nlm.nih.gov/38507814/

  27. Umakanth M, Suganthan N. Unusual manifestations of dengue fever: a review on expanded dengue syndrome. Cureus. 2020; 12 (9): e10678. Available in: https://pmc.ncbi.nlm.nih.gov/articles/PMC7593129/

  28. World Health Organization (WHO). Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. 2011.

  29. WHO and TDR. Dengue guidelines, for diagnosis, treatment, prevention and control. World Health Organization, Vol. 41, 2009, pp. 29-29. Available in: https://books.google.com/books/about/Dengue.html?id=dlc0YSIyGYwC

  30. Muegues-Villero S, Mancilla A, Quinto-Orozco J, Salazar-Campos A, Córdoba-Arenas C. Dengue y sus manifestaciones atípicas en el departamento de Arauca, Colombia 2010- 2015. Revisión de la literatura. JNNPR. 2021; 6: 1387-1407.

  31. Caicedo DM, Méndez AC, Tovar JR, Osorio L. Development of clinical algorithms for the diagnosis of dengue in Colombia. Biomedica. 2019; 39 (1): 170-185. Available in: https://pubmed.ncbi.nlm.nih.gov/31021556/

  32. Khan MAS, Al Mosabbir A, Raheem E, Ahmed A, Rouf RR, Hasan M et al. Clinical spectrum and predictors of severity of dengue among children in 2019 outbreak: a multicenter hospital-based study in Bangladesh. BMC Pediatrics. 2021; 21 (1): 1-10. Available in: https://bmcpediatr.biomedcentral.com/articles/10.1186/s12887-021-02947-y

  33. Srichawla BS, Manan MR, Kipkorir V, Dhali A, Diebel S, Sawant T et al. Neuroinvasion of emerging and re-emerging arboviruses: a scoping review. SAGE Open Med. 2024; 12: 20503121241229847. Available in: https://pubmed.ncbi.nlm.nih.gov/38711470/

  34. Pal S, Roy B, Chattopadhyay A, Andra A, De G. Clinical profile and outcome of dengue patients with atypical features in the pediatric age group in a tertiary care center of East India. Asian J Med Sci. 2021; 12 (11): 133-138. Available in: https://ajmsjournal.info/index.php/AJMS/article/view/2403

  35. Giri S, Anirvan P, Vaidya A, Praharaj DL. Dengue-related acute liver failure-A scoping review. Indian J Gastroenterol. 2024; 43 (2): 407-424. Available in: https://pubmed.ncbi.nlm.nih.gov/38687431/

  36. Ramanan PV, Shruti TK, Rajakumar PS, Sankaranarayanan S. Atypical manifestations of dengue fever in children. J Pediatr Infect Dis. 2021; 16 (2): 53-56. Available in: http://www.thieme-connect.de/products/ejournals/html/10.1055/s-0040-1722285

  37. See KC. Dengue-associated hemophagocytic lymphohistiocytosis: a narrative review of its identification and treatment. Pathogens. 2024; 13 (4): 332. Available in: https://pubmed.ncbi.nlm.nih.gov/38668287/

  38. Centers for Disease Control and Prevention (CDC). Guía de pruebas clínicas para el dengue [Internet]. 2025 [Cited 2025 Aug 7]. Available in: https://www.cdc.gov/dengue/es/hcp/diagnosis-testing/pruebas-clinicas.html

  39. Pourzangiabadi M, Najafi H, Fallah A, Goudarzi A, Pouladi I. Dengue virus: Etiology, epidemiology, pathobiology, and developments in diagnosis and control - A comprehensive review. Infection, Genetics and Evolution. 2025; 127: 105710. Available in: https://www.sciencedirect.com/science/article/pii/S156713482400162X?via%3Dihub

  40. Waickman AT, Lu JQ, Fang HS, Waldran MJ, Gebo C, Currier JR et al. Evolution of inflammation and immunity in a dengue virus 1 human infection model. Sci Transl Med. 2022; 14 (668): eabo5019. Available in: /doi/pdf/10.1126/scitranslmed.abo5019?download=true

  41. Sekaran SD. Dengue diagnostics: the right test at the right time for the right group. Dengue Diagnostics: The Right Test at the Right Time for the Right Group. 2024, pp. 1-107.

  42. Pillay K, Keddie SH, Fitchett E, Akinde C, Bärenbold O, Bradley J et al. Evaluating the performance of common reference laboratory tests for acute dengue diagnosis: a systematic review and meta-analysis of RT-PCR, NS1 ELISA, and IgM ELISA. Lancet Microbe. 2025; 6 (7): 101088. Available in: https://www.thelancet.com/action/showFullText?pii=S2666524725000163

  43. Dengue | Yellow Book | CDC [Internet]. 2025 [Cited 2025 Aug 30]. Available in: https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/dengue.html

  44. Yip WCL. Dengue haemorrhagic fever: current approaches to management. Medical Progress. 1980; 7 (13): 201-209.

  45. Kularatne SAM, Dalugama C, Rajapakse M, Warnasooriya S, Pathirage M, Ralapanawa U et al. Blood transfusion in severe dengue infection: a case series. J Med Case Rep. 2023; 17 (1): 1-10. Available in: https://jmedicalcasereports.biomedcentral.com/articles/10.1186/s13256-022-03716-w

  46. Nakazaki JCF, Cotera-Ramón AI. Assessment of the importance of platelet transfusion in patients with severe dengue: a systematic review. Iberoamerican Journal of Medicine. 2024; 02: 69-77. Available in: http://creativecommons.org/licenses/by/4.0/

  47. Bhalla A, Singh H, Suri V, Yaddanapudi L, Poddar B, Ghawat R et al. ISCCM Position Statement: Management of Severe Dengue in Intensive Care Unit. Indian J Crit Care Med. 2024; 28 (S2): S42-58. Available in: https://pubmed.ncbi.nlm.nih.gov/39234231/

  48. Secretaría de Salud. Lineamientos para la decisión transfusional en personas con infección por dengue. Centro Nacional de Transfusión Sanguínea [Internet]. 2024 [Citado 2025 Agosto 9], Disponible en: https://www.gob.mx/cms/uploads/attachment/file/943504/10-Lineamientosparalatransfusionpordengue.Primeraversion.pdf

  49. Pérez J, LLano López LH, Iramain R, Botta P, Fernández ÁE, Gómez Lund OH et al. Recomendaciones para el manejo del dengue grave pediátrico. Rev Arg de Ter Int. 2025; 42: e942.24012025. Available in: https://revista.sati.org.ar/index.php/MI/article/view/942

  50. Ministerio de Salud, Instituto de Hemoterapia de la Provincia de Buenos Aires "Dra Nora Etchenique." Lineamientos técnicos y recomendaciones ante el brote de dengue. 2024.

  51. Padmaprakash KV, Jha VK, Sowmya Karantha C, Anurag SC, Kamal D, Jambunathan P. Rescue therapy with intravenous immunoglobulin in severe refractory dengue: a pilot study. Med J Armed Forces India. 2022; 78 (2): 204-212. Available in: https://pubmed.ncbi.nlm.nih.gov/35463535/

  52. Tayal A, Kabra SK, Lodha R. Management of dengue: an updated review. Indian J Pediatr. 2023; 90 (2): 168-177. Available in: https://pubmed.ncbi.nlm.nih.gov/36574088/

  53. Kan JY, Chang YJ, Lai HC, Lin HH, Chiu SW, Hung PY, et al. Darunavir inhibits dengue virus replication by targeting the hydrophobic pocket of the envelope protein. Biochem Pharmacol. 2025; 235: 116839. Available in: https://scholar.nycu.edu.tw/en/publications/darunavir-inhibits-dengue-virus-replication-by-targeting-the-hydr

  54. Cherie TJJ, Choong CSH, Abid MB, Weber MW, Yap ES, Seneviratne SL, et al. Immuno-haematologic aspects of dengue infection: biologic insights and clinical implications. Viruses. 2024; 16 (7): 1090. Available in: https://pubmed.ncbi.nlm.nih.gov/39066252/

  55. Wang R, Kim B, Mishra H, Kain KC. Advancing dengue vaccine development: challenges, innovations, and the path toward global protection. Pediatr Investig. 2025; 9 (3): 304-310. Available in: /doi/pdf/10.1002/ped4.70005

  56. Mwandumba H, Choong See K. Dengue vaccination: a practical guide for clinicians. Vaccines. 2025; 13 (2): 145. Available in: https://www.mdpi.com/2076-393X/13/2/145/htm

  57. Deng SQ, Yang X, Wei Y, Chen JT, Wang XJ, Peng HJ. A review on dengue vaccine development. Vaccines. 2020; 8: 63. Available in: https://www.mdpi.com/2076-393X/8/1/63/htm

  58. Lim JK, Lee YS, Wilder-Smith A, Thiry G, Mahoney R, Yoon IK. Points for consideration for dengue vaccine introduction - recommendations by the dengue vaccine initiative. Expert Rev Vaccines. 2016; 15 (4): 529-538. Available in: https://pubmed.ncbi.nlm.nih.gov/26651238/

  59. Kumbhare MR, Chandak SM, Dukare AB, Kshatriya VV, Velhal SS. An updated comprehensive reviewof the dengue vaccine: development, mechanism, efficacy, and safety. J Bio-X Res. 2025; 8: Article0034. Available in: https://doi.org/10.34133/jbioxresearch.003

  60. De Barros Cardoso CR, Cerqueira-Silva T, Barral-Netto M, Boaventura VS. Dengue dilemma: navigating cross-reactivity and immune challenges. Curr Top Microbiol Immunol. 2025. Available in: https://pubmed.ncbi.nlm.nih.gov/40360744/

  61. Aynekulu MDG, van der Sterren I, van Leeuwen LPM, Langerak T, Hakim MS, Martina B et al. The role of antibody-dependent enhancement in dengue vaccination. Trop Dis Travel Med Vaccines. 2024; 10 (1): 1-11. Available in: https://tdtmvjournal.biomedcentral.com/articles/10.1186/s40794-024-00231-2

  62. Guzman MG, Vazquez S. The complexity of antibody-dependent enhancement of dengue virus infection. Viruses. 2010; 2 (12): 2649. Available in: https://pmc.ncbi.nlm.nih.gov/articles/PMC3185591/

  63. Sun DS, Lien TS, Chang HH. Virus-induced pathogenic antibodies: lessons from long COVID and dengue hemorrhage fever. Int J Mol Sci. 2025; 26 (5): 1898. Available in: https://www.mdpi.com/1422-0067/26/5/1898/htm

  64. Ooi EE, Kalimuddin S. Insights into dengue immunity from vaccine trials. Sci Transl Med. 2023; 15 (704): eadh3067. doi: 10.1126/scitranslmed.adh3067. Epub 2023 Jul 12. Erratum in: Sci Transl Med. 2023; 15 (709): eadk1254.

  65. Khandia R, Munjal A, Dhama K, Karthik K, Tiwari R, Malik YS et al. Modulation of dengue/zika virus pathogenicity by antibody-dependent enhancement and strategies to protect against enhancement in zika virus infection. Front Immunol. 2018; 9: 345830. Available in: https://doi.org/10.3389/fimmu.2018.00597




2020     |     www.medigraphic.com